# Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib

> **NCT00890110** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Hadassah Medical Organization** · enrollment: 13 (estimated)

## Conditions studied

- Renal Cell Cancer

## Interventions

- **BIOLOGICAL:** Autologous renal cell vaccine based on DNP modified cells

## Key facts

- **NCT ID:** NCT00890110
- **Lead sponsor:** Hadassah Medical Organization
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-06
- **Primary completion:** 2011-06
- **Final completion:** 2011-12
- **Target enrollment:** 13 (ESTIMATED)
- **Last updated:** 2009-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00890110

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00890110, "Autologous Vaccination of Stage 4 Renal Cell Carcinoma Combined With Sunitinib". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00890110. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*